{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:11:11Z","timestamp":1771920671168,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>The optimal management of early-stage follicular lymphoma (FL) remains an active research area, particularly in China. This retrospective cohort study examined long-term survival outcomes, recurrence patterns, and potential prognostic factors in patients with early-stage FL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 107 patients diagnosed with early-stage FL between 2000 and 2020 at the National Cancer Center in China. Treatment modalities included radiotherapy with or without chemoimmunotherapy or chemotherapy, chemoimmunotherapy or chemotherapy, and observation. Overall survival, progression-free survival, and lymphoma-specific survival were assessed using the Kaplan-Meier method and Cox regression models. We evaluated failure patterns, including locoregional and systemic failures, using cumulative incidence analysis with competing risks. Exploratory LASSO regression and machine learning\u2013based approaches were applied to identify potential prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 53\u00a0years, and the median follow-up was 86\u00a0months. In this 20-year real-world cohort from the National Cancer Center of China (n = 107), long-term outcomes were favorable, with 5- and 10-year rates of 88.7% and 68.8% for OS, 93.3% and 89.9% for LSS, and 76.0% and 57.2% for PFS. No statistically significant differences in survival or cumulative failure were observed across initial management strategies, including radiotherapy with or without systemic therapy, systemic therapy alone, and observation. Recurrence occurred in 21 patients (19.6%), predominantly locoregional (14 locoregional only vs. 6 systemic only; 1 both). The 5- and 10-year cumulative incidences were 16.3% and 19.5% for overall failure, 14.5% and 16.2% for locoregional failure, and 3.1% and 4.8% for systemic failure. POD24 occurred in 6.5% of patients and was associated with inferior OS, although event numbers were limited. Low neutrophil-to-lymphocyte ratio (NLR &amp;lt;1.8) was associated with poorer survival in exploratory analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with early-stage FL in this 20-year real-world Chinese cohort demonstrated an overall favorable long-term prognosis across diverse initial management strategies. No treatment modality showed a clear survival advantage in this limited-size cohort, while relapse was uncommon and more frequently locoregional than systemic. POD24 identified a small subset of patients with inferior survival, highlighting the need for individualized, risk-adapted management and long-term follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1745000","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:30:40Z","timestamp":1768372240000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China"],"prefix":"10.3389","volume":"17","author":[{"given":"Chang","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Zi","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Beijing Hospital, National Geriatric Medical Center","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital","place":["Guiyang, Guizhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Ye","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Wen","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ning","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Lian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Nan","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-Xiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2018","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.anndiagpath.2017.05.005","article-title":"Distribution of lymphoid neoplasms in northwest China: analysis of 3244 cases according to WHO classification in a single institution","volume":"34","author":"Cao","year":"2018","journal-title":"Ann. Diagn Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of follicular lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study","volume":"2","author":"Herfarth","year":"2018","journal-title":"HemaSphere"},{"key":"B12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish lymphoma registry study","volume":"29","author":"Junl\u00e9n","year":"2015","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3904\/kjim.2024.279","article-title":"Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances","volume":"40","author":"Kridel","year":"2025","journal-title":"Korean J. Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood.2021013437","article-title":"POD24 in follicular lymphoma: time to be wise","volume":"139","author":"Leonard","year":"2022","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood.2019004588","article-title":"Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study","volume":"136","author":"Lo","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0609.2010.01445.x","article-title":"Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy","volume":"85","author":"McClanahan","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e12120","DOI":"10.1097\/MD.0000000000012120","article-title":"Epidemiologic characteristics of malignant lymphoma in Hubei, China: a single-center 5-year retrospective study","volume":"97","author":"Meng","year":"2018","journal-title":"Medicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41408-022-00620-w","article-title":"Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma","volume":"12","author":"Sha","year":"2022","journal-title":"Blood Cancer J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjh.12562","article-title":"Incidence of haematological malignancies by ethnic group in England, 2001-7","volume":"163","author":"Shirley","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.18.00854","article-title":"Further examining the TROG 99.03 trial in early-stage follicular lymphoma: cure rate and the role of positron emission tomography","volume":"37","author":"Sorigue","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann. Hematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/bloodadvances.2019000458","article-title":"Outcomes of stage I\/II follicular lymphoma in the PET era: an international study from the Australian lymphoma alliance","volume":"3","author":"Tobin","year":"2019","journal-title":"Blood Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/annonc\/mdy482","article-title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting","volume":"30","author":"van der Gali\u00ebn","year":"2019","journal-title":"Ann. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1016\/S2352-3026(25)00071-7","article-title":"Low-dose moderate hypofractionated radiotherapy for indolent non-hodgkin lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Wang","year":"2025","journal-title":"Lancet Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11864-014-0286-4","article-title":"Radiotherapy of follicular lymphoma: updated role and new rules","volume":"15","author":"Yahalom","year":"2014","journal-title":"Curr. Treat. Options Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2018.79.3075","article-title":"Early-stage follicular lymphoma: what is the preferred treatment strategy?","volume":"36","author":"Yang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","article-title":"Enhancement of the follicular lymphoma international prognostic index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation","volume":"9","author":"Yang","year":"2020","journal-title":"Blood Cancer J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/s41375-020-01042-y","article-title":"Progression-free survival at 24 months and subsequent survival of patients with extranodal NK\/T-cell lymphoma: a china lymphoma collaborative group (CLCG) study","volume":"35","author":"Yang","year":"2021","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","article-title":"PET\/CT in non-hodgkin lymphoma: an update","volume":"53","author":"Zanoni","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/10428194.2023.2283296","article-title":"Impact of age on long-term relative survival benefit of radiotherapy for early-stage grade I-II follicular lymphoma from the SEER database (2000-2015)","volume":"65","author":"Zhong","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41375-020-0963-1","article-title":"Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review","volume":"34","author":"Zhu","year":"2020","journal-title":"Leukemia"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1745000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:06Z","timestamp":1771911546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1745000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1745000"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1745000","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1745000"}}